New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Inhibrx Biosciences, Inc. (INBX) vs Nektar Therapeutics (NKTR)
- Inhibrx Biosciences, Inc. INBX 68.97 −7.21%
- Nektar Therapeutics NKTR 30.20 −7.19%
Inhibrx Biosciences, Inc. and Nektar Therapeutics are both Biotechnology companies. Inhibrx Biosciences, Inc. and Nektar Therapeutics are of similar size ($1.1B and $1.1B). Across the 11 metrics below, Inhibrx Biosciences, Inc. leads on 6 and Nektar Therapeutics on 5.
Valuation
Profitability
| Metric | INBX | NKTR | Biotechnology median |
|---|---|---|---|
| Gross margin | — | 100.00% | 70.18% |
| Operating margin | — | (319.75%) | 0.00% |
| Net margin | — | (339.67%) | 0.00% |
| Free cash flow margin | — | (493.41%) | 0.00% |
| Return on equity | 577.65% | (37.92%) | (51.58%) |
| Return on assets | (71.23%) | (26.48%) | (45.91%) |
| Return on invested capital | 0.00% | (44.31%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack